Overexpression of Multifunctional Protein p32 Promotes a Malignant Phenotype in Colorectal Cancer Cells

Egusquiza-Alvarez, Carlos Alejandro; Castañeda-Patlán, M. Cristina; Albarran-Gutierrez, Sara; González-Aguilar, Héctor; Moreno-Londoño, Ángela Patricia; Maldonado, Vilma; Meléndez-Zajgla, Jorge; Robles-Flores, Martha

doi:10.3389/fonc.2021.642940

Cited by 10 publications

(13 citation statements)

References 48 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…C1QBP interacts with gC1q of C1q, and is involved in the regulation of T cell immunity and regulation of cytokines ( Ricklin et al, 2010 ). C1QBP was found to be closely related to tumorigenesis or metastasis of various cancers ( Bai et al, 2019 ; Xie et al, 2019 ; Peerschke et al, 2020 ; Egusquiza-Alvarez et al, 2021 ; Xie et al, 2021 ). C1S was also observed to promote tumor growth and survival in renal cancer and cutaneous squamous cell carcinoma ( Riihila et al, 2020 ; Daugan et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

A Complement-Related Gene Signature for Predicting Overall Survival and Immunotherapy Efficacy in Sarcoma Patients

Zhang

Lin

Zhou

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The prognoses of sarcomas are poor and the responses of them to systemic therapies are limited and controversial. Thus, there is an urgent need to stratify the risk factors and identify the patients who may benefit from systemic therapies. Here, we developed a reliable, complement-based gene signature to predict the prognosis of sarcoma patients. Survival-related complement genes were identified by univariate Cox analyses and were used to build a gene signature, which was further selected using the least absolute shrinkage and selection operator model, and determined using a stepwise Cox proportional hazards regression model. The whole sarcoma cohort of TCGA was randomly divided into a training set and a test set. The signature was constructed using the training set and validated subsequently in the test set, the whole TCGA sarcoma cohort, and another two independent cohorts from the TARGET and GEO databases, respectively. Furthermore, the prognostic value of the signature was also validated in an independent cohort from our center. This model effectively predicted prognoses across the training set, different validation cohorts, and different clinical subgroups. Next, immune cell infiltration analysis, GO and KEGG analysis, and gene set enrichment analysis were performed to explore possible underlying mechanisms of this signature. Moreover, this signature may predict the response to immunotherapy. Collectively, the current complement-related gene signature can predict overall survival and possible immunotherapy response of sarcoma patients; it may serve as a powerful prognostic tool to further optimize clinical treatment and prognosis management for sarcoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

A Complement-Related Gene Signature for Predicting Overall Survival and Immunotherapy Efficacy in Sarcoma Patients

Zhang

Lin

Zhou

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…For instance, HIF-1α has been associated with growth, metastasis and treatment resistance in breast cancer by activating the PI3K/Akt/mTOR pathway [ 44 ]. C1QBP has also been implicated in Akt/mTOR signaling, which affects the migration capability of colon cancer cells [ 45 ]. TNBCs are reported to have increased expression of HIF-1α [ 46 ] and recently, Wu et al showed that HIF-1α upregulates C1QBP in TNBCs [ 47 ].…”

Section: Discussionmentioning

confidence: 99%

C1QBP Mediates Breast Cancer Cell Proliferation and Growth via Multiple Potential Signalling Pathways

Scully

Sudhaharan

Matsumoto

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast carcinoma is the most prevalent cancer in women globally, with complex genetic and molecular mechanisms that underlie its development and progression. Several challenges such as metastasis and drug resistance limit the prognosis of breast cancer, and hence a constant search for better treatment regimes, including novel molecular therapeutic targets is necessary. Complement component 1, q subcomponent binding protein (C1QBP), a promising molecular target, has been implicated in breast carcinogenesis. In this study, the role of C1QBP in breast cancer progression, in particular cancer cell growth, was determined in triple negative MDA-MB-231 breast cancer cells. Depletion of C1QBP decreased cell proliferation, whereas the opposite effect was observed when C1QBP was overexpressed in MDA-MB-231 cells. Furthermore, gene expression profiling and pathway analysis in C1QBP depleted cells revealed that C1QBP regulates several signaling pathways crucial for cell growth and survival. Taken together, these findings provide a deeper comprehension of the role of C1QBP in triple negative breast cancer, and could possibly pave the way for future advancement of C1QBP-targeted breast cancer therapy.

show abstract

“…Recent researches have shown that gC1qR contributes to cancer progression, invasion and metastasis, and correlates with clinicopathological features of tumors ( Figure 1 ) ( 23 , 52 – 55 ). Its overexpression was found in multiple cancer cells, including breast, ovarian, prostate, melanoma, lung, pancreatic, colon cancer, and malignant pleural mesothelioma ( 55 – 58 ). It has been reported the expression level of gC1qR was correlated with tumor stage, grade, tumor size, and clinical outcome ( 59 , 60 ).…”

Section: Gc1qr In Cancermentioning

confidence: 97%

gC1qR: A New Target for Cancer Immunotherapy

Lei

Qin

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Although breakthroughs in cancer treatment have been achieved, immunotherapy yields only modest benefits in most patients. There is still a gap in clarifying the immune evasiveness and immune-resistance mechanisms. Identifying other candidate targets for cancer immunotherapy is therefore a clear unmet clinical need. The complement system, a pillar of innate immunity, has recently entered the limelight due to its immunoregulatory functions in the tumor microenvironment (TME). In particular, gC1qR, a receptor for globular heads of C1q, serves as a promising new target and has attracted more attention. gC1qR, also named P32/C1qBP/HABP1, is a multifunctional protein that is overexpressed in various cancers and holds prognostic value. It regulates the tumorigenic, progression and metastatic properties of tumor cells through several downstream signaling pathways, including the Wnt/β-catenin, PKC–NF-κB and Akt/PKB pathways. A few preclinical experiments conducted through gC1qR interventions, such as monoclonal antibody, chimeric antigen receptor T‐cell (CAR‐T) therapy, and tumor vaccination, have shown encouraging results in anticancer activity. The efficacy may rely on the regulatory role on the TME, induction of tumor cells apoptosis and antiangiogenic activity. Nevertheless, the current understanding of the relationship between cancer immunotherapy and gC1qR remains elusive and often contradictory, posing both opportunities and challenges for therapeutic translation in the clinic. In this review, we focus on the current understanding of gC1qR function in cancer immunology and highlight the vital roles in regulating the TME. We also examines the rationale behind targeting gC1qR and discusses the potential for translating into clinical practice.

show abstract

Overexpression of Multifunctional Protein p32 Promotes a Malignant Phenotype in Colorectal Cancer Cells

Cited by 10 publications

References 48 publications

A Complement-Related Gene Signature for Predicting Overall Survival and Immunotherapy Efficacy in Sarcoma Patients

A Complement-Related Gene Signature for Predicting Overall Survival and Immunotherapy Efficacy in Sarcoma Patients

C1QBP Mediates Breast Cancer Cell Proliferation and Growth via Multiple Potential Signalling Pathways

gC1qR: A New Target for Cancer Immunotherapy

Contact Info

Product

Resources

About